================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 7, 2006
----------
MOLECULAR DEVICES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
0-27316 94-2914362
(Commission File Number) (IRS Employer Identification No.)
1311 Orleans Drive
Sunnyvale, CA 94089
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (408) 747-1700
----------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On February 7, 2006, Molecular Devices Corporation ("Molecular Devices")
reported its financial results for the quarter ended December 31, 2005. A copy
of the press release issued by Molecular Devices on February 7, 2006 concerning
the foregoing results is furnished herewith as Exhibit 99.1 and is incorporated
herein by reference.
The information in this report, including the exhibit hereto, shall not be
deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of that Section or
Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The
information contained herein and in the accompanying exhibit shall not be
incorporated by reference into any filing with the U.S. Securities and Exchange
Commission made by Molecular Devices, whether made before or after the date
hereof, regardless of any general incorporation language in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
NUMBER DESCRIPTION
- ------ -----------------------------------------------------------------------
99.1 Press release, dated February 7, 2006, entitled "Molecular Devices
Reports Record Revenues and Earnings for Fourth Quarter of 2005,"
issued by Molecular Devices.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MOLECULAR DEVICES CORPORATION
Dated: February 7, 2006 By: /s/TIMOTHY A. HARKNESS
----------------------------
Timothy A. Harkness
Senior Vice President and
Chief Financial Officer
3
EXHIBIT INDEX
NUMBER DESCRIPTION
- ------ -----------------------------------------------------------------------
99.1 Press release, dated February 7, 2006, entitled "Molecular Devices
Reports Record Revenues and Earnings for Fourth Quarter of 2005,"
issued by Molecular Devices.
4